文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > IT/计算机 > 计算机软件及应用 > Bribery claims infect drug companies-Koz analysis
侵权投诉

Bribery claims infect drug companies-Koz analysis

Mark Koznarek Summary

“Stuck between a rock and a hard place”

Many multinational pharmaceutical companies operating in China stand accused of using bribery and other “commissions” to boost sales. GlaxoSmithKline alone is alleged to have paid about $500mm in bribes, and many other companies also stand accused.

This is only the latest of scandals and fines to plague the

pharmaceutical industry. For instance, the US has imposed over $30bil of fines, over the last two decades, for overpricing and illegal marketing.

Yet, the use of “commissions” in the China healthcare market is widespread, and many feel these “commissions” are a necessary part of doing business here, considering the low salaries of doctors.

These investigations are likely to lead to fines in China and perhaps elsewhere. More importantly, slower profit growth in

China is likely, as the scrutiny leads to higher costs of compliance, pricing pressures and slower sales growth. But the substantial long-term opportunities in the China market suggest the industry will “roll with the punches” and pay this price for continued market access.

163 words.

上一页第5页

你可能喜欢

热门文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email